ERCC1 and neoplasm: Finally, the antibody was used in tumor specimens from a stage III CRC cohort, where oxaliplatin remains part of standard treatments, to test its ability to determine varying levels of ERCC1 expression in patient tumors, and therefore also its ability to potentially aid in clinical decision making.